恩利维克斯和60度制药公司将在博电视台讨论有前途的关节骨炎治疗和传染病药物重用. Enlivex and 60 Degrees Pharmaceuticals to discuss promising osteoarthritis treatment and infectious disease drug repurposing on Bloomberg TV.

Enlivex Therapeutics 和 60 Degrees Pharmaceuticals 将于 2025 年 9 月 20 日在彭博电视的 RedChip Small Stocks， Big Money™ 节目中亮相，覆盖美国约 7300 万户家庭。 Enlivex Therapeutics and 60 Degrees Pharmaceuticals will be featured on Bloomberg TV’s RedChip Small Stocks, Big Money™ show on September 20, 2025, reaching an estimated 73 million U.S. homes. Enlivex首席执行官Oren Hershkovitz博士将讨论AllocetraTM在膝骨关节炎方面的积极的第二阶段a结果,重点强调显著减轻疼痛和功能改进,预计2025年11月将进行六个月的数据解读,并计划于2026年进行第二阶段b试验。 Enlivex CEO Dr. Oren Hershkovitz will discuss positive Phase IIa results for Allocetra™ in knee osteoarthritis, highlighting significant pain reduction and functional improvement, with a six-month data readout expected in November 2025 and a Phase IIb trial planned for 2026. 60度首席执行官Geoffrey Dow将重点关注该公司在防治传染病方面的努力,强调在目前和计划进行的临床试验、强大的知识产权以及机构支持的支持下,重新利用林业发展局批准的节育针(ARAKODA)治疗婴儿病等疾病。 60 Degrees CEO Geoffrey Dow will focus on the company’s efforts to combat infectious diseases, emphasizing the repurposing of FDA-approved tafenoquine (ARAKODA®) for conditions like babesiosis, supported by ongoing and planned clinical trials, strong intellectual property, and institutional backing.